MSI1 Gene Solid Tumors clinical trials
33 active Solid Tumors trials that test for MSI1 Gene in their eligibility criteria. Describe your situation to see which ones look like a fit.
- AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors
- A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
- Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors
- A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
- Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
- A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
- A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
- A Study of DS5361b in Participants With Advanced Solid Tumors
- ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu
- Phase II Biomarker Study of SAR444881 in Combination With Cemiplimab in Solid Tumors
- Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
- A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
- A Study of ASP1002 in Adults for Treatment of Solid Tumors
- XTX301 in Patients With Advanced Solid Tumors
- A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
- Lactulose to Improve Gut Health in Cancer Patients Receiving Immunotherapy
- A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors
- A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
- EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
- Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
- A Study of NX-1607 in Adults With Advanced Malignancies
- Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
- Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
- A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
- Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
- Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- A Beta-only IL-2 ImmunoTherapY Study
- Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
- Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
- Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy
- A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
- Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
Guides for people searching for a trial
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.